Alternative Names: Glucocerebrosidase deficiency; Glucosylceramidase deficiency
Gaucher’s disease is a very rare genetic disease in which a fatty substance (lipid) accumulates in cells and certain organs. Gaucher’s disease is the most common of the lysosomal storage diseases:536 It is caused by a hereditary deficiency of the enzyme glucocerebrosidase . The enzyme acts on a fatty substance glucocerebroside (also known as glucosylceramide). When the enzyme is defective, glucocerebroside accumulates, particularly in white blood cells (mononuclear leukocytes). Glucocerebroside can collect in the spleen, liver, kidneys, lungs, brain and bone marrow…….CLICK & SEE THE PICTURES
Symptoms may include enlarged spleen and liver, liver malfunction, skeletal disorders and bone lesions that may be painful, severe neurologic complications, swelling of lymph nodes and (occasionally) adjacent joints, distended abdomen, a brownish tint to the skin, anemia, low blood platelets and yellow fatty deposits on the white of the eye (sclera). Persons affected most seriously may also be more susceptible to infection. Some forms of Gaucher’s disease may be treated with enzyme replacement therapy.
CLICK TO SEE THE PICTURE
The disease is caused by a recessive mutation in a gene located on chromosome 1 and affects both males and females. About 1 in 100 people in the United States are carriers of the most common type of Gaucher disease, while the carrier rate among Ashkenazi Jews is 8.9% while the birth incidence is 1 in 450.
The disease is named after the French doctor Philippe Gaucher, who originally described it in 1882 and lent his name to the condition.The biochemical basis for the disease would be elucidated in 1965.
Gaucher’s disease can occur at any age. It’s most common in Eastern and Central European (Ashkenazi) Jewish people.The National Gaucher Foundation states that around 1 in 100 people in the general U.S. population is a carrier for type 1 Gaucher’s disease, giving a prevalence of 1 in 40,000: among Ashkenazi Jews the rate of carriers is considerably higher, at roughly 1 in 15.
Type 2 Gaucher’s disease shows no particular preference for any ethnic group. Type 3 Gaucher’s disease is especially common in the population of the Northern Swedish region of Norrbotten where the incidence of the disease is 1 in 50,000.
Signs and symptoms of Gaucher’s disease can vary widely from one person to another, particularly among different types of the disease.
The major types of Gaucher’s disease and associated symptoms are:
Type 1. This form of the disease is the most common and is generally the most mild. Type 1 accounts for about 90 percent of cases. In this form of the disease, there’s usually no damage to the brain. This type can occur at any age, although it’s most prevalent in adults, with an average age of 30 at the time of diagnosis. Possible signs and symptoms of type 1 Gaucher’s disease include:
CLICK & SEE
*Skeletal abnormalities, including thinning of your bones (osteopenia), bone pain and bone fractures
*Enlarged liver (hepatomegaly) or spleen (splenomegaly), or both
*A decrease in healthy red blood cells (anemia)
*A greater susceptibility to bruising, which may mean you have a low number of blood platelets (thrombocytopenia)
*Yellow spots in your eyes (pingueculae)
Type 2. This form of Gaucher’s disease is rare and much more severe than the other types. It begins during the first year of life, often developing by 3 months. These babies have brain damage that is extensive and progresses rapidly. In addition to the signs and symptoms listed above, other possible problems that may occur with this type of Gaucher’s include:
CLICK TO SEE THE PICTURE
*Cognitive deterioration, including mental retardation or dementia
Type 3. This form of Gaucher’s disease, also rare, usually begins in childhood or adolescence. It tends to be chronic and progresses more slowly than does type 2.
Although the brain is affected, brain involvement tends to be milder than in type 2. Signs and symptoms, such as enlargement of the liver and spleen, tend to vary more in intensity than in type 2. Signs and symptoms that may occur more in type 3 than in type 1 include:
*Cognitive deterioration, including mental retardation or dementia
*Abnormal eye movements
*Loss of muscle coordination
The disease is caused by a defect in the housekeeping gene lysosomal gluco-cerebrosidase (also known as beta-glucosidase, EC 18.104.22.168, PDB 1OGS) on the first chromosome (1q21). The enzyme is a 55.6 KD, 497 amino acids long protein that catalyses the breakdown of glucocerebroside, a cell membrane constituent of red and white blood cells. The macrophages that clear these cells are unable to eliminate the waste product, which accumulates in fibrils, and turn into Gaucher cells, which appear on light microscopy to resemble crumpled-up paper.
In the brain (type II and III), glucocerebroside accumulates due to the turnover of complex lipids during brain development and the formation of the myelin sheath of nerves.
Different mutations in the beta-glucosidase determine the remaining activity of the enzyme, and, to a large extent, the phenotype.
The risk of having type 1 or 3 Gaucher’s disease or being a carrier is higher if you’re of Eastern or Central European (Ashkenazi) Jewish ancestry. Type 2 is more common in people of Swedish descent.
A family history of any type of Gaucher’s disease increases the risk of being either a carrier of Gaucher’s or of developing the disease.
Heterozygotes for particular acid beta-glucosidase mutations carry about a fivefold risk of developing Parkinson’s disease, making this the most common known genetic risk-factor for Parkinson’s. A study of 1525 Gaucher patients in the United States suggested that while cancer risk is not elevated, particular malignancies (non-Hodgkin lymphoma, melanoma and pancreatic cancer) occurred at a 2-3 times higher rate
Complications of all types
Possible complications of all types of Gaucher’s disease include:
*Bone pain, which can become severe and incapacitating and may be associated with fractures.
*A tendency to bleed, which may result in repeated hemorrhaging in the nostrils or nasal cavities, or bruising beneath the skin (ecchymosis).
*An increased risk of certain cancers. Older people with Gaucher’s disease may have an increased likelihood of developing certain types of cancer, particularly multiple myeloma — uncontrolled multiplication of plasma cells.
Complications of type 2
Complications that are more likely to occur in people with type 2 Gaucher’s disease often include serious neurological complications, such as:
As these problems progress and become more severe, they can become debilitating and lead to death.
Complications of type 3
People with type 3 Gaucher’s disease are more likely to develop calcification of heart valves, which damages the valves and makes it increasingly difficult for them to open fully and function properly.
A definitive diagnosis is made with genetic testing. As there are numerous different mutations, sequencing of the beta-glucosidase gene is sometimes necessary to confirm the diagnosis. Prenatal diagnosis is available, and is useful when there is a known genetic risk factor.
A diagnosis can also be implied by biochemical abnormalities such as high alkaline phosphatase, angiotensin-converting enzyme (ACE) and immunoglobulin levels, or by cell analysis showing “crinkled paper” cytoplasm and glycolipid-laden macrophages.
Some lysosomal enzymes are elevated, including tartrate-resistant acid phosphatase, hexosaminidase, and a human chitinase, chitotriosidase. This latter enzyme has proved to be very useful for monitoring Gaucher’s disease activity in response to treatment, and may reflect the severity of the disease
For type 1 and most type 3 patients, enzyme replacement treatment with intravenous recombinant glucocerebrosidase (imiglucerase) can dramatically decrease liver and spleen size, reduce skeletal abnormalities, and reverse other manifestations. This treatment costs approximately $200,000 annually for a single patient and should be continued for life. The rarity of the disease means that dose-finding studies have been difficult to conduct, so there remains controversy over the optimal dose and dosing frequency. Due to the low incidence, this has become an orphan drug in many countries, meaning that a government recognizes and accommodates the financial constraints that limit research into drugs that address a small population.Velaglucerase alfa was approved by the Food and Drug Administration (FDA) as an alternative treatment on February 26, 2010.
Successful bone marrow transplantation cures the non-neurological manifestations of the disease, because it introduces a monocyte population with active beta-glucosidase. However, this procedure carries significant risk and is rarely performed in Gaucher patients. Surgery to remove the spleen (splenectomy) may be required on rare occasions if the patient is anemic or when the enlarged organ affects the patient’s comfort. Blood transfusion may benefit some anemic patients. Other patients may require joint replacement surgery to improve mobility and quality of life. Other treatment options include antibiotics for infections, antiepileptics for seizures, bisphosphonates for bone lesions, and liver transplants. Substrate reduction therapy may prove to be effective in stopping Type 2, as it can cross through the blood barrier into the brain. There is currently no effective treatment for the severe brain damage that may occur in patients with types 2 and 3 Gaucher disease. Gene therapy may be a future step.
The first effective treatment for the disease, the drug Ceredase, was approved by the FDA in April 1991. An improved drug, Cerezyme, was approved by the FDA in May 1994 and has replaced the use of Ceredase.
Gaucher’s disease has recently become a target for more than one effort at pharmacological chaperoning, which involves the use of orally administered drugs that operate at a molecular level. Miglustat is one of these oral drugs. It was approved for the treatment of this disease in 2003. As of June 2009[update], another oral drug, isofagomine tartrate, is under development.
How well a person does depends on the subtype of the disease. The infantile form of Gaucher disease may lead to early death. Most affected children die before age 5.
Adults with the type 1 form of the disease can expect normal life expectancy with enzyme replacement therapy.
Genetic counseling is recommended for prospective parents with a family history of Gaucher disease. Testing can determine if parents carry the gene that could pass on the Gaucher disease. A prenatal test can also tell if the fetus has Gaucher syndrome.
Disclaimer: This information is not meant to be a substitute for professional medical advise or help. It is always best to consult with a Physician about serious health concerns. This information is in no way intended to diagnose or prescribe remedies.This is purely for educational purpose.
- What is Gaucher disease? (zocdoc.com)
- Three-Year Data From Phase 2 Trial Of Genzyme Gaucher Disease Oral Compound Suggest Sustained Or Further Improvement Across All Endpoints (bioresearchonline.com)
- FDA hands Protalix a CRL for Gaucher’s disease drug (fiercebiotech.com)
- Three-Year Data from Phase 2 Trial of Genzyme Corporation Gaucher Disease Oral Compound Suggest Sustained or Further Improvement Across All Endpoints (biospace.com)
- Genzyme Rival Fails to Get FDA Approval (xconomy.com)
- FDA Approval Delay Sends Protalix Shares Plunging 20% (PLX, PFE, SHPGY, GEN) (businessinsider.com)
- UPDATE 3-U.S. seeks more data on Protalix drug; shares fall (reuters.com)
- This Week’s Health Industry News (prescriptions.blogs.nytimes.com)
- Protalix Shares Plunged: What You Need to Know (fool.com)
- Shire shares fall despite strong rare disease drug sales (telegraph.co.uk)